New Insights into Behçet’s Syndrome Metabolic Reprogramming: Citrate Pathway Dysregulation
Table 1
Demographic and clinical features of all subjects enrolled in the study.
Parameter
Active ()
Inactive ()
Control ()
Age, mean ± SD (years)
41.3 ± 11.3
42.8 ± 13.1
38.1 ± 12.1
Disease duration, mean ± SD (years)
22.8 ± 9.7
21.4 ± 11.4
Male sex, number (%)
12 (66.7)
14 (66.7)
14 (66.7)
Female sex, number (%)
6 (33.3)
7 (33.3)
7 (33.3)
ESR (mm/1 h), mean ± SD
11.3 ± 8.2
12.9 ± 8.2
9.1 ± 6.3
CRP (mg/L), mean ± SD
1.9 ± 2.0
1.5 ± 1.9
0.8 ± 1.2
IL-1β (pg/mL), mean ± SD
463.1 ± 85.9
393.8 ± 124.9
234.4 ± 123.2
BSAS, mean ± SD
34.8 ± 14.7
6.1 ± 7.5
BDCAF, mean ± SD
3.7 ± 1.7
0.8 ± 1.1
One clinical manifestation, number (%)
9 (50.0)
More than one clinical manifestation, number (%)
9 (50.0)
Clinical manifestations, number (%)
Posterior uveitis
7 (38.9)
Oral ulcers
6 (33.3)
Skin lesions
5 (27.8)
Arthritis
4 (22.2)
CNS involvement
1 (5.5)
Vascular involvement
1 (5.5)
All data are presented as mean ± standard deviation except gender and clinical manifestations listed as percentage. ESR = erythrocyte sedimentation rate; CRP = C-reactive protein; BSAS = Behçet’s Syndrome Activity Score; BDCAF = Behçet’s Disease Current Activity Form; CNS = central nervous system.
